Publications by authors named "A van Gameren"

Claim this Profile
O
Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
Wouter A P Breeman, A C Fröberg, E de Blois, A van Gameren, M Melis

Nucl Med Biol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
J P Esser, E P Krenning, J J M Teunissen, P P M Kooij, A L H van Gameren

Eur J Nucl Med Mol Imaging· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
Theodosia Maina, Berthold A Nock, Paul Cordopatis, Bert F Bernard, Wout A P Breeman, Arthur van Gameren

Eur J Nucl Med Mol Imaging· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide.
Marion De Jong, Roelf Valkema, Arthur Van Gameren, Hester Van Boven, Axel Bex

J Nucl Med· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.
Bert Bernard, Astrid Capello, Martin van Hagen, Wout Breeman, Ananth Srinivasan, Arthur van Gameren

Cancer Biother Radiopharm· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis